News & Press

Press Releases

Addressing patient needs through scientific driven innovation

We aspire to become a leading biopharmaceutical company that discovers and develops novel, differentiated therapies in cancer and beyond, addressing critical unmet needs for patients in China and worldwide.

Press Releases
Abbisko Therapeutics Announces Dosing of First Patient in A Phase I Clinical Study of ABSK043 In Australia
Sep 03, 2021
Abbisko Therapeutics Obtained Clinical Trial Approval for ABSK043 in Australia
Jul 12, 2021
Abbisko and Sperogenix Announce An Exclusive Agreement to Develop ABSK021 for ALS and Other Rare Neurological Diseases in Greater China
Jul 05, 2021
Abbisko Therapeutics Announces Dosing of First Patient in A Phase Ib Clinical Study of ABSK011 In China
Jun 29, 2021
Abbisko Therapeutics Announces the Appointment of Mr. Yongyi Li as General Counsel
Jun 04, 2021
Abbisko Therapeutics Announces the Appointment of Ms. Jia Feng as Executive Director and Head of Human Resource
Jun 04, 2021
View all
we discover and develop first-in-class and best-in-class therapies
to address critical unmet needs for cancer patients in China and globally
Media
Abbisko Therapeutics Obtained ABSK091 IND Approval from NMPA
Dec 14, 2020
Abbisko Therapeutics’ Partner X4 Pharmaceuticals Presented Positive Clinical Data from Phase 2 Study of Mavorixafor in WHIM Syndrome
Jun 19, 2020
Abbisko Therapeutics Completes Dosing of the First Patient Cohort for ABSK-021 and The First Patient Enrollment for ABSK-011
Apr 07, 2020
Abbisko Therapeutics Enters into Licensing Agreement with AstraZeneca for Development and Commercialization of AZD4547
Nov 08, 2019
View all

Tel:(+86) 021-68912098

E-MailL:Public@abbisko.com Bd@abbisko.com

Copyright © 2021 All rights reserved:Abbisko Therapeautics     滬ICP備17056565號-1